AURELIA ONLINENot Losing Weight on Mounjaro 15 mg? What to Do When Weight Plateaus at the Maximum Dose
This English page provides medical information and booking guidance. Consultation may be conducted in Japanese or English. Tell the doctor the country where you are physically located. Medication supplied through this service is received in Japan by the patient; proxy pickup and direct overseas delivery are not supported.
Not losing more weight on Mounjaro 15 mg does not automatically mean the drug has stopped working. 15 mg is the maximum labeled dose, and long-term treatment commonly moves from active loss into a maintenance plateau.
- There is no labeled Mounjaro dose above 15 mg.
- Do not shorten the weekly interval or combine extra pens to overcome a plateau.
- A plateau can represent successful maintenance after substantial loss.
- Review bowel function, intake, alcohol, activity, sleep, medications and the medical need for further loss.
- If 15 mg has significant side effects, dose reduction may be more appropriate than trying to “push harder.”
15 mg can still plateau
The 2025 SURMOUNT plateau analysis found that most participants eventually reached a study-defined plateau. Higher target doses were associated with a later plateau, but did not eliminate it. By week 72, roughly 88–90% had reached plateau.
What did 15 mg achieve in SURMOUNT-1?
The 15 mg target group had a mean weight change of −20.9% at 72 weeks. About 57% achieved at least 20% weight loss. These figures also show that response varies widely—15 mg does not guarantee a particular loss.
“Not losing” can mean two very different things
| Pattern | Interpretation |
|---|---|
| 100 kg → 80 kg, then stable at 80 kg | Large loss followed by maintenance plateau |
| Minimal loss throughout treatment despite adequate duration/dose | Limited response; reassess the overall strategy |
Ten things to review at the maximum dose
- How long you have actually been on 15 mg
- 7-day average weight, not a single reading
- Constipation
- Snacks, drinks and alcohol
- Daily steps/NEAT
- Resistance training and muscle function
- Sleep and stress
- Other weight-promoting medicines
- Glucose/HbA1c in type 2 diabetes
- Whether further weight loss is medically necessary
Why continuing treatment can still have value
In SURMOUNT-4, after an initial 36-week tirzepatide phase with average 20.9% loss, participants who continued treatment lost another 5.5% on average from week 36 to 88, while those switched to placebo regained 14.0% on average. Maintaining a large previous loss is part of treatment success.
Should you stop to reset sensitivity?
No established “reset” strategy exists. Withdrawal data show that stopping tirzepatide often leads to weight regain. A pause or restart should be medically planned, not used as a self-directed plateau hack.
Can maintenance dosing be lower than 15 mg?
Yes, depending on the patient. In 2026 SURMOUNT-MAINTAIN, participants who had lost weight on maximum tolerated 10/15 mg were randomized to continue the maximum tolerated dose, reduce to 5 mg, or switch to placebo. At week 112, mean change from original baseline was −21.9%, −16.6%, and −9.9%, respectively. This supports the concept of a lower maintenance dose for some patients, while showing that higher-dose continuation preserved more weight loss on average.
When 15 mg plus side effects is a reason to reconsider
If weight is stable but nausea, constipation, poor intake or excessive weight loss is significant, remaining at 15 mg may not be the best tradeoff. A lower dose can be considered if it maintains the clinical benefit with better tolerability.
At 15 mg, think “next goal,” not “next dose”
The practical question becomes whether the current weight should be maintained, whether further loss is necessary, or whether a lower maintenance dose can hold the benefit. The dose ceiling changes the strategy from escalation to optimization.
Frequently asked questions
Can Mounjaro 15 mg stop producing further weight loss?
Yes. Long-term weight loss commonly slows and plateaus even at the maximum dose.
What comes after 15 mg?
There is no higher labeled Mounjaro dose. The next step is reassessment, not an unapproved higher dose or shorter injection interval.
Does a plateau mean Mounjaro is no longer working?
Not necessarily. If you are maintaining a substantial prior loss and appetite/behavior remain improved, treatment may still be providing maintenance benefit.
Can I reduce the dose if 15 mg is too strong?
A lower maintenance dose may be considered depending on side effects, weight, glucose and treatment goals.
References
- PMDA. Mounjaro Japanese package insert, revision September 2026.
- Horn DB, et al. Time to weight plateau with tirzepatide. Clin Obes. 2025.
- Aronne LJ, et al. SURMOUNT-4. JAMA. 2024.
- Horn DB, et al. SURMOUNT-MAINTAIN. Lancet. 2026.
In Japan, Mounjaro is approved for type 2 diabetes. Use of Mounjaro for weight management is off-label. Obesity-trial data are cited as medical evidence about tirzepatide, not as a statement that Mounjaro is approved for obesity in Japan.